Posted on

Article: DoorDash Soars in IPO to $60 Billion Market Cap

Article - Media, Publications

DoorDash Soars in IPO to $60 Billion Market Cap

Christiana Sciaudone, 09 December 2020

Investing.com — Doordash Inc (NYSE:DASH) is a smash hit. The food-delivery company opened trading at $182, a whopping 78% jump over the $102 at which it priced on Tuesday.

The company sold 33 million shares — originally marketed between $90 and $95 — on Tuesday to raise $3.37 billion in its initial public offering and now has a market value of about $60 billion.

DoorDash’s IPO is the third-largest in the U.S. this year, topped only by Bill Ackman’s $4 billion blank-check company and Snowflake Inc’s (NYSE:SNOW) $3.86 billion offering.
Continue reading “Article: DoorDash Soars in IPO to $60 Billion Market Cap”

Posted on

Article: DoorDash IPO delivers billions to its Stanford founders

Article - Media, Publications

DoorDash IPO delivers billions to its Stanford founders

Tom Maloney, 09 December 2020

Stanford University students Tony Xu, Andy Fang and Stanley Tang had a revelation seven years ago in a Palo Alto macaroon store.

The shop’s owner showed them pages and pages of delivery orders she hadn’t been able to fulfill. Demand wasn’t high enough to hire a full-time delivery person, but there was no way she could drop off all the orders herself. It was a story the three heard again and again as they worked to understand how they could leverage technology to help small businesses.

They decided to build a basic web page with menus from local restaurants to see if there was demand for a delivery business. “It was super simple, ugly, and honestly we weren’t really expecting anything,” Tang said at a Stanford lecture years later. “All of a sudden we got a phone call – someone called! They wanted to order Thai food.”
Continue reading “Article: DoorDash IPO delivers billions to its Stanford founders”

Posted on

Article: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages MultiPlan (MPLN) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud

Article - Media, Publications

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages MultiPlan (MPLN) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud

Globe Newswire, 08 December 2020

The investigation centers on MultiPlan’s financial disclosures leading up to- and through- its merger and going public transaction with special purpose acquisition (“SPAC”) company Churchill Capital Corp. III. More specifically, Hagens Berman is investigating the company’s and its sponsor’s statements about MultiPlan’s client base and revenues. On Nov. 11, 2020, Muddy Waters Capital published a scathing report, “MultiPlan: Private Equity Necrophilia Meets The Great 2020 Money Grab,” based in part on its interviews of former MultiPlan executives.

Among other things, Muddy Waters observes: (1) the company and its sponsors concealed the impending loss of MultiPlan’s largest client (“UnitedHealthcare”, or “UHC”) due to UHC’s formation of a competitor (“Naviguard”) that offers significantly lower prices and fewer conflicts of interest; (2) MultiPlan’s financials “have been financially engineered to obscure the decay in its business;” and, (3) “[w]e understand that in 2018, MPLN released revenue reserves, dropping them from approximately 30% to 10% of revenue, which we believe enabled MPLN to show 2018 EBITDA growth amid shrinking sales.”
Continue reading “Article: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages MultiPlan (MPLN) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud”

Posted on

Article: IBIO – don’t buy the vaccine dream

Article - Media, Publications

IBIO – don’t buy the vaccine dream

mariner_admin, 08 December 2020

IBIO is a Texas-based company whose stock was up ~500% year to date through 12/7 on investor optimism about its COVID-19 vaccine efforts. We believe that IBIO is vaccine vaporware, with a history of having inserted itself into the discourse of several diseases-du-jour over the last decade including H1N1, Ebola, and now COVID. IBIO has never actually commercialized any of its vaccine or therapeutics efforts, having eliminated pipeline disclosure in FY17.

In fact, IBIO settled a shareholder suit alleging that it lied about its Ebola claims, and we believe IBIO’s COVID effort is just a replay of the 2014 Ebola episode. Despite this, the Roberts (Kay and Erwin), have reaped compensation in excess of 100% of IBIO’s revenues since 2008
Continue reading “Article: IBIO – don’t buy the vaccine dream”

Posted on

Article: DoorDash takes a hefty cut from restaurants, and risks losing them to cheaper options

Article - Media, Publications

DoorDash takes a hefty cut from restaurants, and risks losing them to cheaper options

Ari Levy, 08 December 2020

Salvatore Reina owns three Francesca pizzerias in New Jersey that have been closed for indoor dining during the pandemic. While much of his industry turned to DoorDash, Reina resisted.

“Third parties take a big cut,” said Reina, who opened his first pizzeria 12 years ago, about 20 miles outside of New York City. “I’d rather spend those marketing dollars to get people directly.”

As DoorDash prepares for its public market debut, an offering that could value the delivery app service at over $30 billion, the San Francisco-based company has to show that it can make enough money on every order to turn into a profitable business. Meanwhile, investors have to consider how many restaurant owners will eventually turn away from apps like DoorDash because the costs are too high for their low-margin operations.
Continue reading “Article: DoorDash takes a hefty cut from restaurants, and risks losing them to cheaper options”

Posted on

Article: DOORDASH IPO HAS ITS SKEPTICS

Article - Media, Publications

DOORDASH IPO HAS ITS SKEPTICS

Joe Guszkowski, 08 December 2020

Third-party delivery company DoorDash will set a share price for its initial public offering Tuesday, riding a wave of momentum that could bring it a valuation of more than $30 billion.

In the latest sign of demand for its stock, the company on Friday raised the price range for its shares to between $90 and $95, up from $75 to $85.

But not everyone shares that enthusiasm about the IPO. Some investors question the terms of the offering and the company’s readiness for the public market, while others believe its growth runway is shrinking.

On Monday, CtW Investment Group sent a letter to DoorDash’s board raising concerns about the IPO’s share structure and how the company characterized public reaction to a former tipping policy. CtW works with union-sponsored pension funds.
Continue reading “Article: DOORDASH IPO HAS ITS SKEPTICS”

Posted on

Article: Caught in a bear trap: How ‘short and distort’ attacks are costing Australian investors billions

Article - Media

Caught in a bear trap: How ‘short and distort’ attacks are costing Australian investors billions

Adele Ferguson

Sydney Morning Herald,

Australia has become a paradise for a new, aggressive form of short selling. And regulators’ failure to act is costing investors billions.

Dubbed the “short and distort” gang, a group of largely foreign-based research houses issue highly damaging reports, designed to cause maximum damage to the companies they target.

Read full article.

Posted on

Article: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

Article - Media, Publications

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

Zacks Equity Research, 07 December 2020

Launched on 12/20/2011, the VanEck Vectors Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare – Pharma segment of the equity market.

Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors. Continue reading “Article: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?”

Posted on

Article: The Vitol Enforcement Action: Part 1 – Market Manipulation Through Corruption

Article - Media, Publications

The Vitol Enforcement Action: Part 1 – Market Manipulation Through Corruption

Thomas Fox, 07 December 2020

Last week the Department of Justice (DOJ) settled a multi-part enforcement action, partly involving the Foreign Corrupt Practices Act (FCPA), with Vitol Inc. (Vitol), the US subsidiary of Vitol Holding II SA. Vitol agreed to pay a combined $135 million to resolve matters.

Interestingly, also included in the overall settlement was a disgorgement of more than $12.7 million to the Commodity Futures Trading Commission (CFTC) in a related matter and a penalty payment to the CFTC of $16 million related to trading activity. The FCPA component was settled via a Deferred Prosecution Agreement (DPA) and Criminal Information (Information). Continue reading “Article: The Vitol Enforcement Action: Part 1 – Market Manipulation Through Corruption”

Posted on

Article: A Tycoon’s Deep-State Conspiracy Dive

Article - Media, Publications

A Tycoon’s Deep-State Conspiracy Dive

Sheelah Kolhatkar, 07 December 2020

In July, 2015, Patrick Byrne, the founder of the online discount retailer Overstock, delivered a twenty-minute talk at FreedomFest, the annual libertarian conference in Las Vegas. Other speakers included the venture capitalist Peter Thiel; John Mackey, the chief executive officer of Whole Foods; and the Presidential candidate Donald J. Trump.

Byrne’s talk, entitled “Turtles All the Way Down: How the Crypto-Revolution Solves Intractable Problems on Wall Street,” was a version of one he had given many times before. It touched on several of his interests, including the kind of liberalism usually referred to as libertarianism, the flaws in the structure of the stock market which make it vulnerable to manipulation, and how a blockchain-based financial system could eliminate those flaws. After the talk, a line of people waited by the stage to speak to Byrne.
Continue reading “Article: A Tycoon’s Deep-State Conspiracy Dive”

Posted on

Article: Vitol to pay $95.7 million to settle fraud, market manipulation charges

Article - Media, Publications

Vitol to pay $95.7 million to settle fraud, market manipulation charges

Reuters Staff, 04 December 2020

WASHINGTON (Reuters) – Energy and commodities trading firm Vitol Inc has agreed to pay $95.7 million to settle charges of corruption-based fraud and attempted market manipulation, the U.S. Commodity Futures Trading Commission on Thursday.

Houston-based Vitol did not admit or deny the charges, but agreed to pay the civil penalties related to making bribes and offering kickbacks to employees of certain state-owned entities in Brazil, Ecuador and Mexico in exchange for “preferential treatment and access to trades,” the regulator said.

Read Full Article

Posted on

Article: Berman Tabacco Investigates OrthoPediatrics Corp. (KIDS) on Behalf of Investors Concerning Potential Violations of Federal Securities Laws

Article - Media, Publications

Berman Tabacco Investigates OrthoPediatrics Corp. (KIDS) on Behalf of Investors Concerning Potential Violations of Federal Securities Laws

ACCESSWIRE, 03 December 2020

Berman Tabacco, a national law firm representing investors, is investigating potential violations of the federal securities laws by OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ:KIDS) and its officers and directors. OrthoPediatrics is a medical device company based in Warsaw, Indiana. The Company designs, develops, and commercializes orthopedic implants and instruments for children with orthopedic conditions. On December 2, 2020, Culper Research issued a report asserting that it believed that OrthoPediatrics “overstated revenues.” On this news, the Company’s common shares were trading down by as much as 13% on heavy volume.
Continue reading “Article: Berman Tabacco Investigates OrthoPediatrics Corp. (KIDS) on Behalf of Investors Concerning Potential Violations of Federal Securities Laws”

Posted on

Article: Why Nano-X Imaging Stock Continues to Surge

Article - Media, Publications

Why Nano-X Imaging Stock Continues to Surge

Rich Smith, 02 December 2020

Shares of Nano-X Imaging (NASDAQ: NNOX), the Israeli X-ray machine maker with the novel business idea of giving its products away for free (and then taking a cut of the revenue when doctors use the machines to take X-rays), is back in investors’ favor again. Over the past 10 days, shares of Nano-X have surged 79% — including a big 7% jump today as of 2:20 p.m. EST.

Why is Nano-X doing so well today? To learn the answer, you first have to go back in time a couple of months to mid-September, when Citron Research published a report branding Nano-X as “Theranos 2.0” and a company that not only “has never published any data showing their machine’s images compared to images from a standard CT scanner,” but has actually never even showed investors that it has a machine at all.

These and similar accusations from the short-seller devastated Nano-X’s stock over the summer, but on Thursday starting at 11:30 a.m. EST, Nano-X will attempt to refute all of the above by hosting “a live demonstration that will showcase the Nanox digital x-ray source tube and a range of 2D and 3D imaging applications performed by the Nanox.ARC at the 2020 Radiology Society of North America Virtual Annual Meeting.”

Read Full Article

Posted on

Article: DoorDash Gets a Bullish Rating and Price Target Before It Starts Trading

Article - Media, Publications

DoorDash Gets a Bullish Rating and Price Target Before It Starts Trading

Rhian Hunt, 02 December 2020

Food delivery IPO DoorDash, rival to Grubhub (NYSE:GRUB) and other restaurant delivery services, attracted its first major analyst rating even before its shares are actually trading on the stock exchange. The news site Benzinga reported yesterday that investment banking, wealth management, and financial analysis firm D.A. Davidson rated the company as a buy and gave its stock a speculative price target of $93 per share.

Davidson analyst Tom White laid out a bull case for DoorDash based on several metrics, including its 2020 U.S. delivery market share of 50%. That is up from a 36% share at the year’s beginning and 17% two years ago. White also points out that the company still has lots of room for growth, providing service to just 6% of America’s population and handling 3% of off-premise restaurant sales (18 million customers and $8 billion in gross order value, respectively). The $93 price target represents a sixfold multiple of DoorDash’s enterprise-value-to-sales (EV/sales) ratio.
Continue reading “Article: DoorDash Gets a Bullish Rating and Price Target Before It Starts Trading”

Posted on

Article: INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims Against MultiPlan Corporation

Article - Media, Publications

INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims Against MultiPlan Corporation

GLOBE NEWSWIRE, 01 December 2020

On November 11, 2020, Muddy Waters Research (“Muddy Waters”) released a report entitled “MultiPlan: Private Equity Necrophilia Meets The Great 2020 Money Grab.” Among other issues, the Muddy Waters report asserted that Multiplan is “in financial decline, and its financial statements were engineered to obscure this existing deterioration” and that the Company “is in the process of losing its largest client, UnitedHealthcare (‘UHC’),” which “has formed a competitor to MPLN that offers significantly lower prices and fewer conflicts of interest.” On this news, Multiplan’s stock price fell $1.72 per share, or 19.7%, to close at $7.01 per share on November 11, 2020.
Continue reading “Article: INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims Against MultiPlan Corporation”